Total CD34+ cells per 10 HPF in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response following imatinib treatment

AimsBefore the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance of MF at this new era of CML therapy.MethodsThe study cohort consisted of 135 patients with CML who were exposed to imatinib. The grades of MF pre and post imatinib together with cytogenetic and molecular responses were evaluated.ResultsSevere MF (grade II–III) was observed in 44 (33%) patients prior to imatinib therapy, and in 8 (8%) after 12 months of imatinib treatment (p=0.001). The complete cytogenetic response (CCyR) rates at 12 months did not differ according to the pre-imatinib MF grades, and CCyR rates in patients with grades 0, I, II and III MF were 36/47 (76.5%), 26/33 (78.7%), 12/23 (52.1%) and 7/10 (70%), respectively (p=0.127). There was no significant difference between patients with or without CCyR at 12 months of imatinib regarding grades of MF (p=0.785). The distribution of the major molecular response rates at 18 months according to pre-treatment grades of MF were determined as grade 0 in 38/45 (84.4%), grade I in 21/28 (75%), grade II in 14/21 (66.6%) and grade III in 7/10 (70%) (p=0.112). There was no significant difference in overall survival rates between initial MF mild (grade 0–I) and severe (grade II–III) groups (p=0.278).ConclusionsAccording to our findings, MF regresses with imatinib therapy over time, and the MF grades at diagnosis do not have a negative impact on the responses to imatinib treatment. Therefore, the adverse prognostic impact of the MF among patients with CML seems to disappear in the era of the TKIs.

Download Full-text

Ex vivo expansion and characterisation of CD34+ cells derived from chronic myeloid leukaemia bone marrow and peripheral blood, and from normal bone marrowand mobilised peripheral blood

European Journal Of Haematology ◽

10.1034/j.1600-0609.2000.90108.x ◽

2000 ◽

Vol 64 (2) ◽

pp. 85-92 ◽

Cited By ~ 7

Author(s):

Marina I. Garin ◽

Jane F. Apperley ◽

Junia V. Melo

Keyword(s):

Bone Marrow ◽

Chronic Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Peripheral Blood ◽

Ex Vivo ◽

Ex Vivo Expansion ◽

Normal Bone ◽

Cd34 Cells

Download Full-text

A pilot study of continuous imatinib mesylate (IM) versus pulsed imatinib with or without lenograstim (recombinant human granulocyte colony stimulating factor [rHu-GCSF]) in chronic myeloid leukaemia (CML) patients who have achieved a complete cytogenetic response

http://isrctn.org/> ◽

10.1186/isrctn56578157 ◽

2013 ◽

Author(s):

Tessa Holyoake

Keyword(s):

Pilot Study ◽

Chronic Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Imatinib Mesylate ◽

Cytogenetic Response ◽

Granulocyte Colony Stimulating Factor ◽

Colony Stimulating Factor ◽

Complete Cytogenetic Response ◽

Stimulating Factor

Download Full-text

Percentage of CD34+ cells in a minimum 500-cell count in bone marrow trephines of patients with chronic myeloid leukaemia provides the best correlation with aspirate blast count

British Journal of Haematology ◽

10.1111/j.1365-2141.2005.05620.x ◽

2005 ◽

Vol 130 (3) ◽

pp. 460-461 ◽

Cited By ~ 4

Author(s):

V. Elliot ◽

D. Marin ◽

D. Horncastle ◽

K. Elderfield ◽

J. F. Apperley ◽

...

Keyword(s):

Bone Marrow ◽

Chronic Myeloid Leukaemia ◽

Cell Count ◽

Myeloid Leukaemia ◽

Cd34 Cells ◽

Blast Count

Download Full-text

Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic Response 5-Year Survival Is as High as for Early Chronic Phase Patients.

Blood ◽

10.1182/blood.v108.11.2156.2156 ◽

2006 ◽

Vol 108 (11) ◽

pp. 2156-2156

Author(s):

Ilaria Iacobucci ◽

Giovanni Martinelli ◽

M. Amabile ◽

A. Poerio ◽

S. Soverini ◽

...

Keyword(s):

Bone Marrow ◽

Overall Survival ◽

Bone Marrow Cells ◽

Chronic Phase ◽

Working Party ◽

Progression Free Survival ◽

Cytogenetic Response ◽

Molecular Response ◽

Imatinib Treatment ◽

Complete Cytogenetic Response

Abstract Background: Imatinib (IM) is the drug of choice for the treatment of Ph+ CML, where a complete cytogenetic response (CCgR) is achieved in more than 80% of early chronic phase (ECP) patients, with a 5-year survival of 90% (Simonsson B, Blood 2005). In the patients who initiated the treatment in late chronic phase (LCP) the response rate is lower and the long-term effect on survival is not yet determined. Aim: We monitored the hematologic, cytogenetic and molecular response to IM in a cohort of 291 patients who were treated with IM in LCP, with focus on progression-free survival and overall survival of complete cytogenetic responders. Methods: Two hundred and ninety-one patients with Ph+ CML in LCP were enrolled in a national prospective study of the GIMEMA CML Working Party in 2001, and were monitored for cytogenetic response and for molecular response every 6 months. Cytogenetics was performed on bone marrow cells with conventional methods. Molecular response was assessed on bone marrow or peripheral blood samples by quantitative PCR (RQ-PCR) using TaqMan methodology and expressing the results as a ratio of BCR-ABL to ABL x100. Patient age ranged from 19 to 82 years (median 52 years). The duration of chronic phase prior to IM treatment ranged from 1 to 202 months (median 38 months). Treatment was IM 400 mg daily through all the study period, with a few exceptions of dose increase to 600 or 800 mg. The median follow-up time after the first IM dose is 62 months. Results: One hundred and sixty patients (55%) achieved a CCgR in 3 to 62 months (median 6 months) after the first IM dose and 126 of them (79%) are still in continuous CCgR after 5 years. For the 160 patients the 5-year survival free from progression to accelerated or blastic phase is 95% and overall survival is 91%. These data are very similar to those reported for the ECP patients in the IRIS study (Simonsson B, Blood 2005). At 5 years, 107 patients were evaluated for molecular response; 62% of them were in major molecular response with a BCR-ABL/ABL ratio lower than 0.10. The BCR-ABL transcript was undetectable in 7 cases by RQ-PCR and in 2 cases by nested PCR. No patient developed heart failure. Conclusions: We confirm that in LCP the CCgR rate to IM is lower than in ECP, but we show that for the complete cytogenetic responders progression-free and overall survival are likely to be as good as for ECP patients, suggesting that the quality of the CCgR is prognostically more important than the duration of leukemia prior to IM treatment. Figure Figure

Download Full-text

Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients

European Journal of Internal Medicine ◽

10.1016/j.ejim.2013.11.002 ◽

2014 ◽

Vol 25 (1) ◽

pp. 63-66 ◽

Cited By ~ 15

Author(s):

Alessandra Iurlo ◽

Anna Ubertis ◽

Silvia Artuso ◽

Cristina Bucelli ◽

Tommaso Radice ◽

...

Keyword(s):

Chronic Myeloid Leukaemia ◽

Elderly Patients ◽

Myeloid Leukaemia ◽

Cytogenetic Response ◽

Complete Cytogenetic Response

Download Full-text

Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy

Case Reports in Ophthalmological Medicine ◽

10.1155/2015/713868 ◽

2015 ◽

Vol 2015 ◽

pp. 1-3 ◽

Cited By ~ 1

Author(s):

Eric K. Newcott ◽

Abdallah A. Ellabban ◽

Shokufeh Tavassoli ◽

Ahmed Sallam

Keyword(s):

Chronic Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Macular Oedema ◽

Intravitreal Bevacizumab ◽

Imatinib Therapy ◽

Cystoid Macular Oedema ◽

Imatinib Treatment ◽

Intravitreal Triamcinolone ◽

Fellow Eye

Purpose.To evaluate the efficacy of intravitreal bevacizumab and triamcinolone in the treatment of cystoid macular oedema in a case with chronic myeloid leukaemia on imatinib treatment.Methods.We treated a 78-year-old man with bilateral cystoid macular oedema with intravitreal triamcinolone and subsequent bevacizumab in one eye and intravitreal bevacizumab, alone, in the fellow eye.Results.Serial intravitreal bevacizumab with and without triamcinolone treated cystoid macular oedema in both eyes and improved the vision.Conclusion.Intravitreal bevacizumab and triamcinolone could be viable options to treat cystoid macular oedema due to chronic myeloid leukaemia and imatinib therapy.

Download Full-text